Oncolytics is developing pelareorep, an IV delivered I-O agent, which introduces double-stranded RNA into cancer cells. Contact company: https://xitter.cf/t.co/sNAsxxiOi5
San Diego, California
Joined March 2009
- Tweets1.9K
- Following386
- Followers2.9K
- Likes82
Updated #AnalCancer data show median OS has not yet been reached, but all responding patients survived beyond 12 months and median DOR is ~15 months, which compares favorably to historical benchmarks. More on this and the HPV strategy for #pelareorep here: ir.oncolyticsbiotech.com/pre…
At #ESMO26 we will highlight our randomized, controlled REO 033 #ColorectalCancer study. It is designed to validate previous efficacy signals showing #pelareorep + standard of care more than doubled historical benchmarks. Learn more in the PR: ir.oncolyticsbiotech.com/pre… #ESMO2026
Data from the GOBLET study has been critical for the development of #pelareorep. @PanCAN helped fund Cohort 5 of GOBLET, and we are now expecting a final grant payment by year-end. We thank them for their efforts and look forward to upcoming milestones: ir.oncolyticsbiotech.com/pre…
We continue to expand patent protection for #pelareorep into the late 2040s through a newly issued method of use patent, 3 patent application families pending, and development of a potential composition of matter patent to support "next generation" pela: ir.oncolyticsbiotech.com/pre…
We believe #pelareorep can be a backbone immunotherapy. An academic paper shows pela transforms the TME to be immunologically active in liver cancer, which is notoriously challenging. This can enable immunotherapies like checkpoint inhibitors to work: ir.oncolyticsbiotech.com/pre…
Nearly all of our planned sites for the REO 033 #ColorectalCancer study are now open. Enrollment is accelerating, and we anticipate having interim data to report by year-end, which will be critical as we consider the potential pivotal Part B expansion: ir.oncolyticsbiotech.com/pre…
#RAS inhibitors are one of the most important emerging classes of cancer therapy. Today, we show pelareorep can reduce tumor growth alone and in combination with a pan-RAS inhibitor compared to a control in a preclinical RAS-driven colorectal cancer model: ir.oncolyticsbiotech.com/pre…
As a result of FDA’s written feedback and alignment on our REO 033 #ColorectalCancer study, we will forgo a Type D meeting and will pursue an End-of-Phase meeting. Notably, a Part B expansion could support accelerated approval based on ORR and DOR: ir.oncolyticsbiotech.com/pre…
Where could pelareorep go next?
Today, we’re focused on GI tumors, where unmet need is high and data is building. Biology suggests the potential doesn’t stop there.
Full @ZacksSmallCap interview: scr.zacks.com/news/news-deta…
Oncolytics Biotech retweeted
Jared Kelly, CEO of Oncolytics Biotech Inc. (ONCY), joins WTR Healthcare Happenings in this episode for a discussion on the company's progress advancing pelareorep, its investigational oncolytic virus immunotherapy for difficult-to-treat gastrointestinal cancers.
- The significant unmet need in RAS-mutated colorectal, pancreatic, and anal cancers — tumor types largely left behind by immunotherapy advances
- How pelareorep's systemically delivered mechanism selectively targets tumor cells while stimulating an anti-cancer immune response
- Recent clinical results, upcoming data readouts, regulatory progress, and Oncolytics' strategy for registration-directed colorectal cancer studies and partnerships
Listen here on all platforms or website:
Platforms: pod.link/1795488592
Website: watertowerresearch.com/media…
$ONCY #Oncolytics #Pelareorep #GastrointestinalCancer #ColorectalCancer #PancreaticCancer #Immunotherapy #OncolyticVirus #Biotech #ClinicalTrials #Oncology #DrugDevelopment #HealthcareInvesting #SmallCap #WTR @Oncolytics
The FDA has granted Fast Track designation to pelareorep in advanced anal cancer, supporting development for patients with no approved options after first‑line therapy. This marks its third Fast Track designation in GI cancers.
🔗 Read more: ir.oncolyticsbiotech.com/pre…
ALT Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
CEO Jared Kelly highlights the challenges and opportunities biotechs face designing clinical trials that maintain investor engagement while pursuing overall survival + how #pelareorep and oncolytic viruses may offer unique advantages in cancer treatment: biopharminternational.com/vi…
When immunotherapy fails, the drug isn't always the problem. Often it comes down to getting the drug to the tumor. Dr. Richard Vile discusses our work to trigger a powerful immune response directly within the tumor microenvironment. More on @endpts: webinars.endpoints.news/from…
Our REO 033 #ColorectalCancer study is expected to have half of the planned clinical sites activated by the end of this month and we are scheduled to meet with the FDA to discuss a pathway that supports both potential accelerated and full approval: ir.oncolyticsbiotech.com/pre…
In metastatic colorectal cancer, traditional immunotherapies often hit a wall because the immune system can't get past the front door. Dr. Van Morris breaks down how a novel approach could change the game from the inside out. Full @endpts webinar: webinars.endpoints.news/from…
Patent protection for #pelareorep has been extended into 2044 with the granting of a new patent covering its manufacturing process. Intellectual property is a cornerstone of pelareorep’s development, and we have or will file more patents. Here is the PR: ir.oncolyticsbiotech.com/pre…
We have appointed Steve Glover to the Oncolytics Board and promoted John McAdory to Chief Operating Officer. Both will play crucial roles as we position #pelareorep as an immunotherapy backbone for #GastrointestinalCancer patients. Read the PR here: ir.oncolyticsbiotech.com/pre…
As a result of positive anti-tumor activity for #pelareorep and a #RAS inhibitor, Oncolytics plans to explore combinations with multiple #KRAS and RAS inhibitors in RAS-mutated tumor models, supporting our work in #ColorectalCancer and #PancreaticCancer
ir.oncolyticsbiotech.com/pre…
⏳ 2 days to go
Register now to join @endpts for a live discussion on systemic viral immunotherapy as a backbone strategy in GI oncology, with insights on CRC & SCAC study design and regulatory pathways.
📅 May 28 | 🕚 11:30–12:30 ET webinars.endpoints.news/from…
At #ASCO26, we’ll present translational data showing pelareorep, an investigational IV immunotherapy, is associated with expansion of mutant KRAS-specific‑specific T‑cell clones in blood, supporting its relevance in RAS‑driven GI cancers. ir.oncolyticsbiotech.com/pre…
ALT Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors